Clinical Trials ·
This study investigates how liver function affects the pharmacokinetics of Retatrutide (LY3437943). It specifically evaluates the absorption and elimination of the drug in participants with varying degrees of liver impairment compared to those with normal liver function, alongside an assessment of safety and tolerability.
What this source covers
The study, registered under ClinicalTrials.gov (NCT05916560), aims to measure the pharmacokinetics of LY3437943 in individuals with mild, moderate, and severe liver impairment. It compares these findings to healthy participants with normal liver function. The study duration for each participant may extend up to nine weeks, including the screening phase, and will also focus on the safety and tolerability of the drug.
Why it matters for Retatrutide research
Understanding how liver function affects the pharmacokinetics of Retatrutide is crucial, as liver health can significantly influence drug metabolism and efficacy. This study's findings could inform dosing strategies and safety profiles for patients with liver conditions, thereby enhancing the therapeutic application of Retatrutide in diverse populations.
Key findings or claims
- The study assesses the pharmacokinetics of LY3437943 in participants with varying degrees of liver impairment.
- It compares these results to those from healthy participants with normal liver function.
- Safety and tolerability of LY3437943 will be evaluated throughout the study.
- The study duration for each participant may last up to nine weeks.
- Participants will include those with mild, moderate, and severe liver impairment.
Context and prior work
Retatrutide is part of a class of medications that target GLP-1, GIP, and glucagon receptors, which are pivotal in metabolic regulation. Previous studies have indicated that liver function can alter the pharmacokinetics of various drugs, making this research particularly relevant in the context of Retatrutide's therapeutic use. Understanding these interactions can help tailor treatment regimens for patients with liver conditions, ensuring both efficacy and safety.
Practical takeaways for researchers
This study provides valuable insights into the pharmacokinetics of Retatrutide in populations with liver impairment, which could influence future clinical guidelines and research directions. Researchers focusing on Retatrutide should consider the implications of liver function on drug metabolism when designing studies or interpreting results. Additionally, findings from this research may serve as a foundation for further exploration into the safety and efficacy of Retatrutide in patients with liver diseases.
FAQ
What is the primary focus of the study on LY3437943?
The primary focus is to measure how much LY3437943 enters the bloodstream and how long it takes the body to eliminate it in participants with different levels of liver function.
How long will the study last for each participant?
The study may last up to nine weeks for each participant, including the screening period.
What aspects of LY3437943 are being evaluated in this study?
The study evaluates the pharmacokinetics, safety, and tolerability of LY3437943 in participants with impaired and normal liver function.
Source: ClinicalTrials.gov · NCT05916560 · published 2025-04-18.